You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage

    SBC: NEUROP, INC.            Topic: 102

    Abstract Subarachnoid hemorrhageSAHremains a serious source of neurological morbiditywith approximatelycases reported in the US each yearDespite advances in treating the initial and subsequent bleedspost surgical clipping of the aneurysm is associated with a significant risk of delayed cerebral ischemiaDCIThese events typically occur within the firstdays after aneurysmal rupture and DCI remains th ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced therapeutic for Parkinson's Disease

    SBC: Inhibikase Therapeutics, Inc.            Topic: 105

    Parkinson s DiseasePDis a progressive neurodegenerative disorder that affectsmillion patient in the U Sannually andtomillion people worldwidePD is characterized by disorders of movementwhich are caused by the progressive loss of dopamine neurons in the substantia nigra pars compactaSNpcand autonomic dysfunctionanxietydepressionsleep disorders and cognitive impairment that are due to the degenerati ...

    SBIR Phase II 2017 Department of Health and Human Services
  3. Low Cost Multi-pathogen Laser Diagnostic for HIV and AIDS Co-Infections

    SBC: Precision Photonics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Diagnosis and medical management of HIV-infected individuals is significantly enhanced if one can simultaneously define the subset of the most common co-infections for which patients are at risk. Unfortunately, running such a series of parallel diagnostic tests is cost prohibitive, particularly in low-resource settings. Precision Photonics Corporation proposes ...

    SBIR Phase II 2009 Department of Health and Human Services
  4. Clinical Development of Combination Plague/Smallpox Vaccine

    SBC: INVIRAGEN, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The threat of terrorist attacks using biological weapons continues to be a major national security issue. A new congressional report (www.preventwmd.gov, Dec 3, 2008) indicates that a terrorist attack with bioweapons or other weapons of mass destruction might occur before 2013. Plague and smallpox could be devastating bioweapons if intentionally released. A rel ...

    SBIR Phase II 2009 Department of Health and Human Services
  5. Economic Spectroscopic Evaluation of Cervical Cancer

    SBC: GUIDED THERAPEUTICS            Topic: N/A

    DESCRIPTION (provided by applicant): Guided Therapeutics has developed the LightTouch(R), a non invasive, point of care device that uses a combination of fluorescence and reflectance spectroscopy to measure the entire ecto-cervix in an imaging format. Our test is intended for use prior to colposcopy by a trained healthcare professional (e.g., physician, nurse practitioner, physician's assistant) t ...

    SBIR Phase II 2009 Department of Health and Human Services
  6. Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II

    SBC: MBC Pharma, Inc.            Topic: NCI

    Project Summary AbstractThe overall aim of this project is to further develop a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastasesThe conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate IbandronateThe novel conjugate directly addresses the limi ...

    SBIR Phase II 2017 Department of Health and Human Services
  7. Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: 102

    Abstract The liver is the most common organ for metastasis of various cancersincluding pancreaticovariancolorectalgastric cancers and melanomaUveal melanoma metastasizes inof patients and upon metastasis targets the liver inof these casesThe most common primary malignant liver cancer worldwide is hepatocellular carcinomaHCCThe use of blind liver biopsy as a diagnostic tool for liver cancer has man ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced PML antiviral

    SBC: Inhibikase Therapeutics, Inc.            Topic: NIAID

    Inhibikase Therapeutics is a clinical stagebiopharmaceutical company that has developed a hosttargeted mechanism of action to treat AIDS related and drug induced progressive multifocal leukoencephalopathyPMLPML is a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the midsDuring the height of the epidemicthe rate of PML o ...

    SBIR Phase II 2017 Department of Health and Human Services
  9. IND enabling studies for a personalized immunotherapy for triple negative breast cancer

    SBC: METACLIPSE THERAPEUTICS CORPORATION            Topic: NCI

    Abstract The worldwide incidence of breast cancer ismillionTriple negative breast cancersTNBCaccount forof total breast cancer casesworldwideAnnuallyovernew cases of TNBC are diagnosed in the US aloneThe treatment options for TNBC patients are limitedTriple negative breast cancerTNBCincludes breast cancers that lack estrogen receptorprogesterone receptorand HERproteinsLack of known targets and pat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Sealing Air Leaks by Inductive Coagulation Following Lung Surgery

    SBC: ROCKY MOUNTAIN BIOSYSTEMS INC            Topic: N/A

    DESCRIPTION (provided by applicant): Close to 342,000 Americans die of lung disease each year, particularly from lung cancer and chronic obstructive pulmonary disease (COPD). This makes lung disease America's number three killer, responsible for one in every seven deaths. In general, for lung cancer or COPD, resection presents the best chance of survival and an agreeable quality of life. The most ...

    SBIR Phase II 2009 Department of Health and Human Services
US Flag An Official Website of the United States Government